Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
    • One-pager
    • Slide presentation
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival
September 10, 2022
CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne
March 3, 2023
November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison

CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities.
biotech-internship

This position would provide a unique educational experience in more than one way:
  • An explosion of pet ownership and associated pet-related therapies has created an unparalleled demand for USDA regulatory experts. The qualified intern will get a unique opportunity to learn the USDA regulatory process.
  • Along with the USDA work, the intern will communicate with FDA personnel and act as a content liaison while assisting the internal team with day-to-day FDA questions.
  • This position also provides an opportunity to work alongside an international team in the establishment of both US and international clinical trial programs.
  • Project scope includes biological work for veterinary USDA, human FDA pre-IND, human phase II ex-US, and medical device programs.

We are a pure startup culture. Nothing matters more than your output. Flexible balance between onsite (Boston) vs. remote workul>

Please send your application to

Dr. Alexander Shneider ashneider@curelab.com

Share

Related posts

March 3, 2023

CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne


Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

177 HUNTINGTON
AVE FL 17
BOSTON MA 02115-3156
© 2020 CureLab Oncology.